R&D Layout
Platform Construction
Upholding the philosophy of openness and collaboration, KVVIT Pharmaceutical adheres to independent innovation in core technological fields to sustain long-term core competitiveness.
Across multi locations, we have built collaborative and efficient pharmaceutical innovation platforms in Shanghai, Hangzhou, Ganzhou and Beijing, forming a full-chain innovation and R&D system.
R&D Headquarters, New Drug Design & Screening Platform, Biomedical Innovation Accelerator.
- R&D Headquarters. Located in Shanghai's Zhangjiang High-Tech Park, a leading hub for China's biopharmaceutical industry, it is equipped with advanced instruments and equipment for new drug R&D.
- New Drug Design & Screening Platform. It focuses on target design and screening of small-molecule innovative drugs to address unmet clinical needs, covering oncology, antiviral therapy, immunomodulation and other related fields.
- Biomedical Innovation Accelerator. It is the world’s largest Class A biomedical innovation accelerator, invested and established by the controlling shareholder of KVVIT Pharmaceutical.
Innovative Drug CMC Transformation Platform, High-end Generic Drug R&D Platform, Polymorph Research Platform.
It serves as a lab-scale research and formulation development platform for innovative drugs and high-end generic drugs. The R&D center covers a total area of 10,000 square meters, staffed by over 130 dedicated R&D personnel. All experimental platforms are designed and constructed in compliance with EU GMP, US FDA CGMP, and China GMP standards. The center, guided by an open philosophy, is capable of undertaking third-party drug R&D services.
Special Formulation Research Platform, Pilot-Scale and Technology Transfer Platform.
- Special Formulation Research Platform. It has successfully established advanced technology research platforms, including sustained and controlled release, hot melt extrusion, and osmotic pump systems, forming the core technological advantages of KVVIT Pharmaceutical.
- Pilot-Scale and Technology Transfer Platform. It is equipped with standardized laboratories and advanced domestic and international instruments, capable of independently conducting lab-scale and pilot-scale studies for new drugs, as well as technology transfer.
Registration Affairs, Clinical Center, Intellectual Property.
It is mainly engaged in new drug clinical development, registration application and intellectual property management, including
registration applications, clinical site selection, Standard Operating Procedure (SOP) development, project management and quality control, and rapid patient enrollment. A multidisciplinary clinical research network has been established, covering areas such as oncology, cardiovascular diseases, and neurological disorders (the Company also operates clinical research platforms in Shanghai, Nanjing, and other locations).
R&D Headquarters, New Drug Design & Screening Platform, Biomedical Innovation Accelerator.
- R&D Headquarters. Located in Shanghai's Zhangjiang High-Tech Park, a leading hub for China's biopharmaceutical industry, it is equipped with advanced instruments and equipment for new drug R&D.
- New Drug Design & Screening Platform. It focuses on target design and screening of small-molecule innovative drugs to address unmet clinical needs, covering oncology, antiviral therapy, immunomodulation and other related fields.
- Biomedical Innovation Accelerator. It is the world’s largest Class A biomedical innovation accelerator, invested and established by the controlling shareholder of KVVIT Pharmaceutical.
Innovative Drug CMC Transformation Platform, High-end Generic Drug R&D Platform, Polymorph Research Platform.
It serves as a lab-scale research and formulation development platform for innovative drugs and high-end generic drugs. The R&D center covers a total area of 10,000 square meters, staffed by over 130 dedicated R&D personnel. All experimental platforms are designed and constructed in compliance with EU GMP, US FDA CGMP, and China GMP standards. The center, guided by an open philosophy, is capable of undertaking third-party drug R&D services.
Special Formulation Research Platform, Pilot-Scale and Technology Transfer Platform.
- Special Formulation Research Platform. It has successfully established advanced technology research platforms, including sustained and controlled release, hot melt extrusion, and osmotic pump systems, forming the core technological advantages of KVVIT Pharmaceutical.
- Pilot-Scale and Technology Transfer Platform. It is equipped with standardized laboratories and advanced domestic and international instruments, capable of independently conducting lab-scale and pilot-scale studies for new drugs, as well as technology transfer.
Registration Affairs, Clinical Center, Intellectual Property.
It is mainly engaged in new drug clinical development, registration application and intellectual property management, including
registration applications, clinical site selection, Standard Operating Procedure (SOP) development, project management and quality control, and rapid patient enrollment. A multidisciplinary clinical research network has been established, covering areas such as oncology, cardiovascular diseases, and neurological disorders (the Company also operates clinical research platforms in Shanghai, Nanjing, and other locations).
Talent Supply
A strategy rooted in R&D is, in essence, a strategy driven by talent. Centering on Shanghai and adopting a multi-location layout, the Company attracts and gathers high-caliber talent worldwide by building high-level R&D and innovation platforms.
Research Projects
The Company has undertaken a series of major provincial and municipal special science and technology projects as well as key R&D programs.
